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•No differences in sur-
vival or CNS relapse
were seen, and delays
after i-HD-MTX were
reduced by delivering
R-CHOP before day 10.
High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with
diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse.
However, there is limited evidence to guide whether to intercalate HD-MTX (i-HD-MTX)
between R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisolone given at 21-day intervals) or to give it at the end of treatment (EOT) with
R-CHOP-21. We conducted a retrospective, multicenter analysis of 334 patients with DLBCL
who received CNS prophylaxis with i-HD-MTX (n 5 204) or EOT HD-MTX (n 5 130). Primary
end points were R-CHOP delay rates and HD-MTX toxicity. Secondary end points were CNS
relapse rate, progression-free survival, and overall survival. The EOT group had more
patients with a high CNS international prognostic index (58% vs 39%; P , .001) and more
concurrent intrathecal prophylaxis (56% vs 34%; P , .001). Of the 409 cycles of i-HD-MTX
given, 82 (20%) were associated with a delay of next R-CHOP (median, 7 days). Delays
were significantly increased when i-HD-MTX was given after day 9 post–R-CHOP (26% vs
16%; P 5 .01). On multivariable analysis, i-HD-MTX was independently associated with
increased R-CHOP delays. Increased mucositis, febrile neutropenia, and longer median
inpatient stay were recorded with i-HD-MTX delivery. Three-year cumulative CNS relapse
incidence was 5.9%, with no differences between groups. There was no difference in
survival between groups. We report increased toxicity and R-CHOP delay with i-HD-MTX
compared with EOT delivery but no difference in CNS relapse or survival. Decisions on
HD-MTX timing should be individualized and, where i-HD-MTX is favored, we recommend
scheduling before day 10 of R-CHOP cycles.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma,1
comprising ;40% of all cases of lymphoma in large population-based registries. Despite being an
aggressive malignancy, the majority of cases can be cured with R-CHOP chemoimmunotherapy
(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) given at 21-day intervals.
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Systemic progression or relapse remains the most common
cause of treatment failure in DLBCL, but central nervous
system (CNS) relapse may also occur either in isolation or in
combination with systemic disease recurrence. The prognosis
from CNS relapse is dismal, with most studies reporting a median
survival of ,6 months.2,3 Estimates of incidence of CNS relapse
in DLBCL vary from 2% to 6%, with some discrepancy across
published studies as to whether the introduction of rituximab has
reduced this risk.4-7
Various patient and disease characteristics have been identified
that confer a high risk of CNS relapse in DLBCL, including the
total number of extranodal sites involved,8 involvement of specific
high-risk sites (eg, testicular, breast), advanced stage disease, and
increased lactate dehydrogenase (LDH) levels.9 Recently, the CNS
international prognostic index (CNS-IPI) has increasingly been used
to identify high-risk patients; this index was derived from a large
population of patients in clinical trials for DLBCL and validated in
a “real-world” registry.10 It incorporates all standard IPI features
as well as an additional point for renal and/or adrenal involvement.
Although the evidence for identifying patients at increased risk of
CNS relapse is relatively robust, data on the most effective way to
reduce this risk are lacking, with many studies being retrospective
and incorporating significant selection bias. Intrathecal (IT) chemo-
therapy (eg, methotrexate [MTX]), incorporated into R-CHOP
therapy, was used for many years as a prophylactic regimen.
However, with an increased recognition that the pattern of CNS
relapse in DLBCL is predominantly parenchymal,11,12 an area
inadequately penetrated by IT chemotherapy,13 there has been
increased focus on the use of systemic prophylaxis such as
intravenous high-dose MTX (HD-MTX). Indeed, several recent pub-
lications have cast further doubt on any benefit of IT prophylaxis14,15 as
well as highlighting the potential for toxicity with this approach.16
Although several studies have suggested that HD-MTX is effective
CNS prophylaxis in DLBCL,15,17,18 no prospective randomized trial
has been performed to show the benefit of this strategy, and there
remains a lack of consensus regarding how it should be deliv-
ered (ie, timing, number of cycles, dose). CNS relapses tend to
occur early, with the median time from DLBCL diagnosis to CNS
relapse reported in most studies at between 6 and 8 months.12,19
Therefore, there is rationale to deliver CNS prophylaxis as early as
possible during treatment. “Intercalating” HD-MTX between cycles
of R-CHOP has been adopted in many centers. However, the
largest published study demonstrating this as a deliverable and
effective strategy was retrospective in nature, single center, and
included only 65 patients.18 Given that failure of systemic therapy in
DLBCL poses a much greater risk than CNS relapse, concern
exists that the toxicity of intercalated HD-MTX (i-HD-MTX) may
compromise delivery of R-CHOP therapy. An alternative approach
is to wait until completion of systemic therapy before delivering HD-
MTX with the aim to retain R-CHOP dose intensity, albeit with
concern that such a delay in delivery may not abrogate early CNS
relapse in some patients.
To address this clinically important and unanswered question, we
conducted a retrospective, multicenter national analysis of patients
with DLBCL who had received R-CHOP therapy as well as CNS
prophylaxis with HD-MTX. Within this large data set, our primary aim
was to analyze the toxicity of HD-MTX and its effect on R-CHOP
relative dose intensity, comparing an i-HD-MTX approach to delivery
at end of treatment (EOT). Secondary aims were to determine
whether there were differences in survival and relapse outcome
(including rates of CNS recurrence).
Methods
Data on 334 consecutive patients with DLBCL who received R-CHOP
given at 21-day intervals in addition to HD-MTX CNS prophylaxis
between 2011 and 2018 were collected from 11 centers in the United
Kingdom who used either the i-HD-MTX or the EOT approach
according to center preference. Patients with transformed indolent non-
Hodgkin lymphoma were included, but patients with HIV-associated
DLBCL, posttransplant or immunosuppression-related lymphoprolifer-
ative disorders, and any patients with known CNS involvement at
diagnosis were excluded. Baseline CNS evaluation was not mandated
but was performed according to local treating clinician discretion for
patients with clinical suspicion of CNS disease at diagnosis. Patients
receiving additional IT prophylaxis were not excluded.
Patients were selected for CNS prophylaxis per local policies on the
basis of published risk models, including involvement of$2 extranodal
sites plus increased LDH levels9 or high CNS-IPI score,10 or due to
involvement of specific high-risk sites (testicular, renal/adrenal, breast,
paranasal sinus, paraspinal, or ovarian involvement).
Baseline characteristics were collected, including several risk
factors known to influence CNS relapse rates. Continuous variables
are expressed as median and range; intergroup comparisons were
performed by using theMann-WhitneyU test. Categorical variables are
presented as proportions and were compared by using the x2 test.
R-CHOP was scheduled in 21-day cycles for all patients. R-CHOP
delays were analyzed in 2 ways. First, all cycles of i-HD-MTX admin-
istered were reviewed and any delays to subsequent R-CHOP cycles
recorded, with univariable and multivariable analyses (MVA) of risk
factors for delay performed using logistic regression. Second, to
determine if i-HD-MTX was an independent risk factor for delay,
an analysis of all R-CHOP delays throughout therapy for both
groups was performed, including MVA with timing of HD-MTX
included as a risk factor.
Progression-free survival (PFS), overall survival (OS), and time to
CNS relapse were determined by using Kaplan-Meier survival
analysis20 and Cox regression with comparison between treatment
groups made using the log-rank test. Time-to-event analyses were
measured from the date of initial DLBCL diagnosis. An “event” for
PFS was defined by CNS or systemic relapse, or death from any
cause. Patients were censored at the date last seen if alive and
event free. Time-to-CNS relapse and the cumulative incidence of
CNS relapse at 2 and 3 years were calculated. Landmark survival
analyses of PFS, OS, and CNS relapse were performed for patients
who were alive and event free at 6 months from diagnosis to
address potential immortality bias. Statistical analyses were per-
formed by using IBM SPSS Statistics for Windows, version 26 (IBM
SPSS Statistics, IBM Corporation, Armonk, NY) with 95% confi-
dence intervals presented and P , .05 considered significant.
Results
Baseline characteristics
Baseline characteristics of all 334 patients are summarized in
Table 1, with further stratification by timing of HD-MTX (i-HD-MTX
[n5 204] vs EOT [n5 130]). Across both cohorts, the median age
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was 61 years (range, 20-82 years) with a male predominance
(59%). Sixty-two percent had involvement of $2 extranodal sites,
and 46% had a high CNS IPI (score, 4-6). Only 3% had “double-hit”
lymphoma (presence of MYC with BCL2 and/or BCL6 trans-
locations), reflecting the preference in most centers to treat such
patients with more intensive regimens than R-CHOP. Ninety-
six percent of patients received 6 cycles of R-CHOP, and the
median number of cycles of HD-MTX delivered was 2 (range,
1-4 cycles).
Baseline characteristics were broadly similar between the 2
treatment groups. Of note, the EOT group had a higher proportion
of patients with poor performance status and with renal/adrenal
involvement; as a result, more patients were in the high CNS-IPI
category in this group. A higher proportion of patients in the EOT
group (73 of 130 [56%]) received IT prophylaxis in addition to HD-
MTX compared with the intercalated group (69 of 204 [34%]). The
most frequently used IT chemotherapy was MTX, with a median
number of treatments of 2 (range, 1-6).
Delays with i-HD-MTX
A total of 409 cycles of HD-MTX were given intercalated between
cycles of R-CHOP from 204 patients. Eighty-two (20%) of these
were associated with a delay in the subsequent R-CHOP cycle,
with a median delay of 7 days (range, 2-150 days). Clinicians were
asked to determine whether they felt the R-CHOP delay was
directly attributable to HD-MTX. Fifty-six (14%) of 409 cycles had
an R-CHOP delay attributed to MTX, with reasons for delay as
follows: infection (n5 19), mucositis (n5 11), cytopenias (n5 10),
renal toxicity (n5 7), delayed MTX clearance (n5 2), hepatotoxicity
(n 5 2), and other/unknown (n 5 4). Delays were significantly
increased when i-HD-MTX was given after day 9 following R-CHOP
(48 of 185 [26%] vs 32 of 207 [16%]; P 5 .01). Univariable and
multivariable analysis of factors associated with R-CHOP delay
after intercalated MTX identified that delivering MTX later in the
R-CHOP cycle (on or after day 10) was the most significant
factor contributing to R-CHOP delay (Table 2). Full details of
timing of delivery of i-HD-MTX are displayed in supplemental
Figure 1.
Table 1. Baseline characteristics
Characteristic All patients (N 5 334) Intercalated (n 5 204) EOT (n 5 130) P
Age, median (range), y 61 (20-82) 60 (20-81) 62 (20-82) .78
Male sex 197 (59) 116 (57) 81 (62) .32
Creatinine clearance, median (range), mL/min 111 (44-299) 115 (45-299) 107 (44-236) .03*
Advanced stage 266 (82) 168 (82) 107 (82) .99
Elevated LDH 242 (72) 143 (70) 99 (76) .33
ECOG PS $2 88 (27) 45 (22) 44 (34) .02*
1 EN site 123 (37) 81 (40) 42 (32) .38
2 EN sites 116 (35) 66 (32) 50 (38)
$3 EN sites 90 (27) 55 (27) 35 (27)
Renal/adrenal involvement 55 (16) 26 (13) 29 (22) .02*
“Double hit”† 10 (3) 5 (3) 5 (4) .65
CNS-IPI
Low (0-1) 51 (16) 32 (16) 19 (15)
Intermediate (2-3) 123 (35) 88 (45) 35 (27)
High (4-6) 151 (46) 77 (39) 74 (58) ,.001*
IT prophylaxis 142 (42) 69 (34) 73 (56) ,.001*
Received 6 cycles of R-CHOP 319 (96) 194 (95) 125 (96) .65
No. HD-MTX received, median (range) 2 (1-4) 2 (1-4) 2 (1-3) .62
Received $3 g/m2 HD-MTX 309 (93) 191 (94) 118 (91) .33
Data are n (%) unless otherwise noted. Missing data: LDH, n 5 8; PS, n 5 3; Renal/adrenal involvement, n 5 2; Double hit, n 5 38; CNS-IPI, n 5 9. ECOG PS, Eastern Cooperative
Oncology Group performance status; EN, extranodal; IT, intrathecal.
*Statistically significant.
†Presence of MYC with BCL2 and/or BCL6 translocations.
Table 2. Univariable and multivariable analysis of factors influencing
delay of subsequent R-CHOP when i-HD-MTX given
Parameter
Univariable Multivariable
Odds ratio (95% CI) P Odds ratio (95% CI) P
i-HD-MTX given after
day 9 post R-CHOP
1.92 (1.16-3.16) .01* 1.74 (1.03-2.93) .04*
Age 1.02 (1.00-1.04) .07 1.02 (0.99-1.05) .16
Male sex 1.41 (0.86-2.32) .17 1.50 (0.88-2.56) .13
Advanced stage 0.61 (0.34-1.11) .11 0.56 (0.26-1.21) .14
ECOG PS $2 0.84 (0.52-1.71) .84 0.98 (0.52-1.84) .94
No. extranodal sites 0.95 (0.74-1.20) .65 1.00 (0.76-1.33) .98
Elevated LDH 1.12 (0.65-1.93) .70 1.72 (0.87-3.40) .12
Baseline creatinine
clearance
1.00 (0.99-1.00) .16 1.00 (0.99-1.01) .80
Missing data: day of i-HD-MTX, n 5 17.
*Statistically significant.
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Comparison of R-CHOP delays between
treatment groups
Sixty-five (32%) of 203 patients in the i-HD-MTX group had at least
one R-CHOP delay during therapy of$7 days compared with 18 of
119 (15%) in the EOT group (P 5 .001). Ninety (44%) of 203 had
at least 1 delay of $3 days in the i-HD-MTX group compared with
27 of 119 (23%) in the EOT group (P, .001). Further breakdown of
number of cycles delayed for each patient is outlined in supplemen-
tal Table 1. On multivariable analysis of the whole cohort, including
several baseline and prognostic factors, intercalation of HD-MTX
and male sex were the only parameters independently associated
with increased R-CHOP delays (Table 3).
MTX toxicity
Toxicity data were collected for a total of 729 cycles of HD-MTX
(Table 4). The overall rate of renal toxicity was 5% and was similar
across groups. Focusing on the period post–HD-MTX administra-
tion, i-HD-MTX was associated with significantly increased muco-
sitis (10% vs 4%; P 5 .001), neutropenic fever (10% vs 2%; P ,
.001), and longer median inpatient stay (5 vs 4 days; P , .001),
likely reflecting the delivery of MTX during the neutrophil nadir after
R-CHOP.
Survival outcomes and CNS relapse
There were 19 CNS relapses in the whole study cohort (5.7%), with
a median time from diagnosis to relapse of 8.1 months (range, 5-46
months). Fourteen were parenchymal (74%), 2 (11%) involved both
the parenchyma and leptomeninges, and 3 (16%) were isolated to
the leptomeninges. Four of the five patients with leptomeningeal
involvement at relapse had received concurrent IT prophylaxis. Two
of the patients who experienced a CNS relapse had only received 1
cycle of HD-MTX (both in the i-HD-MTX group), with the remainder
receiving $2 cycles.
The overall estimated 2- and 3-year cumulative incidence of CNS
relapse was 5.1% (95% CI, 2.7-7.5) and 5.9% (95% CI, 3.0-8.8),
respectively. According to HD-MTX timing, the 3-year cumulative
incidence of CNS relapse was: i-HD-MTX, 6.8% (95% CI, 2.9-
10.7); and EOT, 4.7% (95% CI, 1.0-8.4). There was no statistically
significant difference between the groups (unadjusted hazard ratio,
1.21; 95% CI, 0.48-3.07; P 5 .691) (Figure 1A).
On univariable analysis, the only significant risk factor for CNS
relapse identified was involvement of$2 extranodal sites (P5 .04).
Timing of HD-MTX and use of IT prophylaxis were not associated
with CNS relapse risk on MVA (supplemental Table 2). There was
no reduction in CNS relapse rate in the 72 patients in the EOT
group who had IT prophylaxis compared with those who did not
(5.8% vs 5.5%; P 5 .96).
An analysis focusing on patients who developed early CNS relapse
(defined as earlier than 8 months from original DLBCL diagnosis)
identified 9 patients in this category, with clinical and prognostic
features described in supplemental Table 3. Of note, these patients
were enriched for high-risk features such as advanced stage and
raised LDH levels (all patients), number of extranodal sites (5 of 9
with $3 extranodal sites), and renal or adrenal involvement (4 of 9
patients). However, 4 of 9 patients did not fall into the high-risk
CNS-IPI category (due to age #60 years and Eastern Cooperative
Oncology Group performance status ,2). The outcomes were
poor, with all but 1 patient dying of lymphoma. Of note, 6 of
9 patients had concurrent systemic progression at the time of
CNS relapse.
With a median follow up of 2.4 years (range, 0.3-8.7 years), the
3-year PFS and OS of the i-HD-MTX group were 71.2% (95% CI,
64.0-78.4) and 80.6% (95% CI, 73.8-87.4), respectively, and in the
EOT group, 3-year PFS and OS were 76.3% (95% CI, 68.2-84.5)
and 85.3% (95% CI, 78.1-92.6). There was no statistically
significant difference in either PFS (P 5 .26) or OS (P 5 .32)
between the groups (Figure 1B-C). On landmark analysis including
only those who were alive and event-free at 6 months, there
remained no difference in PFS, OS, or CNS relapse rate between
the 2 groups (supplemental Figure 2). No significant difference in
CNS relapse, PFS, or OS was seen when analysis was restricted
to patients with high CNS-IPI, but an increased risk of treatment
delays remained with i-HD-MTX (data not shown). There was
no significant difference in 3-year PFS between patients who did
or did not have $1 R-CHOP delay of $7 days (66.8% vs 75.1%;
P 5 .12).
Table 3. Univariable and multivariable analysis of factors associated
with R-CHOP delays in whole study population
Parameter
Univariable Multivariable
Odds ratio (95% CI) P Odds ratio (95% CI) P
i-HD-MTX 2.64 (1.48-4.72) .001* 3.06 (1.62-5.77) .001*
Age 1.01 (0.99-1.03) .58 1.00 (0.97-1.03) .88
Baseline creatinine
clearance
1.00 (0.99-1.01) .78 1.00 (0.99-1.01) .39
Male sex 1.60 (0.95-2.70) .08* 1.84 (1.04-3.26) .04*
Advanced stage 0.82 (0.43-1.56) .54 0.69 (0.29-1.63) .40
ECOG PS $2 0.81 (0.45-1.43) .46 0.86 (0.46-1.60) .63
$2 extranodal sites 1.23 (0.73-2.07) .44 1.76 (0.89-3.45) .10
Elevated LDH 0.91 (0.51-1.60) .73 0.94 (0.50-1.91) .94
IT therapy given 0.63 (0.38-1.06) .08 0.74 (0.42-1.30) .29
HD-MTX dose 0.76 (0.45-1.30) .31 0.65 (0.37-1.16) .14
*Statistically significant.








No. of inpatient days,
median (range)
5 (2-60) 5 (2-60) 4 (3-80) ,.001*
Toxicity
Renal (any) 38 (5) 21 (5) 17 (5) .92
Grade 1 (creatinine
1.5-1.9 3 baseline)
22 (3) 12 (3) 10 (3)
Grade 2 (creatinine
2-2.9 3 baseline)
6 (1) 3 (1) 3 (1)
Grade 3 (creatinine
.3 3 baseline)
10 (1) 6 (1) 4 (1)
Liver (grade 2 or worse) 17 (2) 7 (2) 10 (3) .21
Mucositis 54 (7) 42 (10) 12 (4) .001*
Neutropenic fever 49 (7) 42 (10) 7 (2) ,.001*
Data are n (%) unless otherwise noted.
*Statistically significant.
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Discussion
CNS prophylaxis in DLBCL is a contentious issue, with wide
variation in practice throughout the United Kingdom and worldwide.
This disparity is largely due to the paucity of robust, prospective
evidence to guide how patients are selected for prophylaxis and the
optimum method of delivery. Cumulatively, there appears to be
sufficient data to suggest that intravenous HD-MTX is an effective
method for delivering CNS prophylaxis. Although the median time
from diagnosis to CNS relapse reported in most studies is 6 to 8
months,12,19 early CNS relapses during primary R-CHOP therapy
do occur. Therefore, although not supported by prospective data,
there is theoretical rationale for administering HD-MTX as early as
possible. However, HD-MTX can result in significant toxicity, and
careful patient selection is crucial. Patients at highest risk of CNS
relapse are also those at greater risk of systemic treatment failure,
and there are concerns that delivering HD-MTX in an intercalated
fashion with R-CHOP may compromise the timing and relative dose
intensity of systemic therapy. Some clinicians fear that this risk
outweighs the relatively low likelihood of early CNS relapse, and
they choose to wait until after R-CHOP completion before admin-
istering HD-MTX.
To the authors’ knowledge, this multicenter retrospective analysis
of 334 patients is the largest of its type, specifically assessing
the deliverability and toxicity of HD-MTX as CNS prophylaxis with
R-CHOP chemoimmunotherapy, either intercalated or delivered at
the end of systemic treatment. We have shown that intercalating
a cycle of HD-MTX resulted in a delay of the subsequent R-CHOP
cycle in 20% of instances, with a median delay of 7 days. Although
clinicians reported that the HD-MTX itself caused a delay in 14% of
cycles, delays due to the inherent toxicity of R-CHOP are inevitable
for some patients, and it is difficult to ascertain the true contribution
of HD-MTX in these delays.
We addressed this issue by comparing patients receiving i-HD-MTX
vs those who received it after R-CHOP; the latter group acted as
a “control” to show how many delays are seen with R-CHOP alone
in this high-risk patient group. We acknowledge that those who
received EOT HD-MTX were potentially more likely to have
completed R-CHOP therapy without significant complication, and
there may be a degree of selection bias in using this group as
a control for delays. However, we found that 32% of patients in the
intercalated group had at least one R-CHOP delay of $7 days
compared with only 15% in the EOT group. Importantly, on
multivariable analysis, timing of MTX (intercalated vs EOT) was the
only independent risk factor influencing number of R-CHOP delays.
Although a delay of $3 days may not be considered clinically
relevant in isolation, it should be noted that 15% of patients in the
intercalated group had $2 delays of $3 days during treatment
compared with only 1% in the EOT group.
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End of treatement: 117 85 48 32 16 9 3 3
Group 3 year OS 95% CI P-value
Intercalated 80.6% 73.8-87.4
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End of treatement: 105 74 40 28 14 8 2 2
Group 3 year PFS 95% CI P-value
Intercalated 71.2% 64.0-78.4





Group 3 year CI CNS relapse 95% CI P-value
Intercalated 6.8% 2.9-10.7
End of treatment 4.7% 1.0-8.4
0.69
Figure 1. CNS relapse rates and survival outcomes according to timing of HD-MTX CNS prophylaxis. (A) Cumulative incidence of CNS relapse according to
HD-MTX timing. (B) PFS according to HD-MTX timing. (C) OS according to HD-MTX timing.
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Although we have shown that i-HD-MTX increased the risk of
R-CHOP delay, the clinical significance of this finding is a matter for
debate. Given the need to maintain dose intensity in a high-grade,
proliferative malignancy such as DLBCL, delays of $7 days might
be considered as potentially clinically relevant. This is particularly
concerning in this patient cohort who are inherently at high risk of
systemic relapse, as shown by a median IPI of 3 and 123 (37%) of
334 with an IPI of 4 to 5. On analysis of all patients who experienced
a delay of $7 days, there was a trend toward improved PFS in the
no delay group, but this did not reach statistical significance. We
should acknowledge there may be other confounding variables
associated with delay that we have not identified in this retrospec-
tive analysis. Furthermore, it should be noted that for 56 of the
65 patients in the i-HD-MTX group who had a delay of $7 days,
the rest of the cycles were delivered with no further delays of
a similar length.
When considering patients for i-HD-MTX CNS prophylaxis, clini-
cians must assess the patients’ fitness for such an approach.
However, other than ensuring adequate renal function, this is done
in a mainly subjective manner, and often it can be difficult to predict
the tolerability of this approach in individual patients. From this data
set, we attempted to identify factors that may help identify patients
more likely to experience R-CHOP delays after i-HD-MTX. Timing
of i-HD-MTX following R-CHOP was the most significant factor
identified on both univariable and multivariable analyses, with
a higher rate of delay seen when i-HD-MTX was given on day 10
or later. Therefore, based on these data, it may be more suitable to
bring forward i-HD-MTX to earlier within the R-CHOP 21-day cycle
to minimize the risk of delay to the next treatment. It is recognized
that such an approach cannot be substantiated with high-quality
evidence and may lead to as-yet unidentified toxicities.
The rate of CNS relapse in the entire cohort was low (5.7%).
Although the study was not designed or powered to address the
efficacy of HD-MTX CNS prophylaxis, given the high-risk nature of
the patient group, this does seem to be a relatively low rate of CNS
recurrence. For example, patients with a high CNS IPI (score, 4-6)
have a predicted 2-year CNS relapse rate of 10.2%10; 151 patients
in our study fell into this category but had a 2-year CNS relapse risk
of 6.4%. We feel that we have provided some indirect evidence of
efficacy of HD-MTX CNS prophylaxis but acknowledge that this is
an area requiring further investigation, ideally within the setting of
a prospective randomized trial. Furthermore, with such a low event
rate, it is difficult to draw definitive conclusions on any potential
difference in CNS relapse risk when considering the different
approaches for delivering HD-MTX. However, there did not seem to
be any signal toward a difference in CNS recurrence between the 2
strategies.
Toxicity is the main concern when selecting patients for HD-MTX,
and it was therefore important to assess and quantify the frequency
of various toxicities in this real-world cohort. Accepting that this is
a patient group deemed by clinicians to be “fit” for HD-MTX, we
showed that renal toxicity occurred in 5% of HD-MTX cycles, with
the majority being relatively mild and only 2% of cycles causing
grade 2 toxicity or worse. There was a significant increase in
mucositis and infection after i-HD-MTX, which is likely to be the main
explanation for the longer median inpatient stay with this approach.
The main limitations of the current study are those inherent to
retrospective, nonrandomized observation analyses, with some
imbalances in baseline characteristics between groups. We ac-
knowledge that selection criteria for CNS prophylaxis varied
between centers, reflecting the limited evidence to guide such
decisions, particularly before the introduction of the CNS-IPI.
Survival outcomes were a secondary end point of the study with no
preplanned power calculation, and thus there is a risk that the study
is underpowered to detect a difference in PFS or OS between the 2
groups. There is also potential for survivorship bias in retrospectively
identifying patients who had HD-MTX after R-CHOP completion, as
data from those who progressed early or died before R-CHOP
completion may not have been captured. However, data from recent
large prospective trials suggest that the number of patients with
disease progression or treatment-related mortality during R-CHOP
induction therapy is very small (approximately ,5%).21-23 Further-
more, on landmark analysis including only those who were alive and
event free at 6 months, there remained no difference in PFS, OS, or
CNS relapse rate between the groups.
Despite a higher proportion of patients with high CNS-IPI in the
EOT group, there appeared to be no increased CNS relapse with
this approach. However, the number of patients receiving IT therapy
in this group (56%) may be considered a confounding factor.
Accepting the caveat of low event rates in a retrospective analysis,
in the EOT group there was no increase in CNS relapse rate in the
54 patients who had no IT therapy, and in the whole study
population use of IT therapy was not found to be a significant
predictor for CNS relapse on multivariable analysis. Furthermore,
there is growing evidence to suggest that IT therapy is ineffective in
reducing CNS relapses in DLBCL,14-16 although no prospective
trial has definitively answered this question.
The current study addressed 2 methods for HD-MTX delivery
(intercalated or at end of R-CHOP therapy), but a potential third
option is to attempt delivery at the beginning of treatment. This
approach was investigated in a recent phase 2 trial in which HD-
MTX was given with the first 2 cycles of 14-day R-CHOP therapy,
followed by an additional 4 cycles of 14-day R-CHOP and
etoposide with IT cytarabine given as further CNS prophylaxis.24
Although the rates of systemic and CNS relapse were low, whether
this intensive approach is deliverable in a routine clinical setting
remains to be seen. Other potential methods for reducing CNS
relapse in DLBCL under investigation mainly involve incorporation
of novel agents capable of crossing the blood–brain barrier. For
example, ibrutinib, a Bruton tyrosine kinase inhibitor, has shown
activity in CNS involvement of mantle cell lymphoma,25 lympho-
plasmacytic lymphoma,26 and DLBCL.27 Similarly, the immuno-
modulatory agents lenalidomide and pomalidomide have shown
activity in primary and secondary CNS involvement with B-cell
malignancies.28,29 Both ibrutinib and lenalidomide have failed to
show overall benefit for patients with DLBCL when incorporated
into R-CHOP therapy in large phase 3 trials30,31; whether these
drugs could specifically benefit the small subset of patients at high
risk of CNS relapse remains an unanswered question.
In conclusion, although our data suggest that HD-MTX may be
deferred until EOT with less risk of causing R-CHOP delay, the
clinical significance of such delays is unclear, and the additional
value of IT therapy during R-CHOP in this setting remains uncertain.
There continues to be theoretical rationale for intercalating HD-MTX
with R-CHOP to reduce the risk of very early CNS relapse and,
where this approach is favored, we recommend that HD-MTX is
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scheduled before day 10 of the R-CHOP cycle to minimize risk of
delay to the next treatment. Delivery at EOT seems to be a valid
alternative strategy, particularly where there is concern about
fitness and ability to maintain R-CHOP dose intensity, accepting
a risk that early CNS relapse may not be prevented. In the absence
of a prospective, randomized trial to inform decision-making in this
area, our data may help make a careful analysis of competing risks
on an individual patient basis.
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